Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discvry LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -0.74% 200.00p 199.00p 203.00p 203.00p 199.00p 201.00p 46,043 11:05:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 36.5 -14.3 -8.4 - 300.00

Horizon Discvry Share Discussion Threads

Showing 1026 to 1048 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
DateSubjectAuthorDiscuss
17/10/2018
07:12
It is the perception of good value - ValueAct would not be doubling their stake to 10% if they did not regard HZD as good value so I am happy as a long term holder to see their support of the Company. Happier this morning to see they have upped their stake to 13.3%.
jurgenklopp
17/10/2018
00:43
on what basis are they good value?
kestelmill
15/10/2018
10:56
I assume Woodford has sold 3,900,000 shares to ValueAct. ValueAct have a reputation for being long term, supportive holders, so very good news for holders but maybe not for short term wheeler dealers. At current levels the shares would appear to be very good value.
jurgenklopp
15/10/2018
10:42
So the share price takes a steep vertical dive! Explain, please.
bouleversee
15/10/2018
10:30
ValueAct have doubled their stake to 10%.
jurgenklopp
04/10/2018
12:17
Horizon Discovery (HZD) News Out Just Now http://crweworld.com/article/news-provided-by-globenewswire/825335/celyad-announces-exclusive-agreement-for-horizon-discoverys-shrna-platform-to-develop-next-generation-allogeneic-car-t-therapies
danieldanj
18/9/2018
18:14
I wonder why Woodford has reduced his fund's holding.
bouleversee
18/9/2018
16:20
In the slides it says £1.4M investment into Avvinity post-period end. I would like to more info regarding how that project is developing given that level of investment
kestelmill
18/9/2018
08:43
Wot's going on here?
gersemi
18/9/2018
02:40
Yesterday's interims presentation: htTps://www.youtube.com/watch?v=pdfoYBcyK5w&feature=youtu.be hTtps://www.horizondiscoveryplc.com/category/presentations-recordings/
rambutan2
18/9/2018
02:17
Bit more meat on the bone here: httPs://www.ft.com/content/ff8ec5e0-b9bd-11e8-8274-55b72926558f
rambutan2
17/9/2018
11:56
The chart on my ii account is showing a vertical drop to 2.14 at 11 a.m. and immediately back up again. What do you suppose went on there?
bouleversee
17/9/2018
11:25
Could be ValueAct topping up !! 7.4 million shares is a tremendous show of faith from someone. ;o)
jurgenklopp
17/9/2018
11:19
5% of the HZD's shares have just traded, with a huge amount of other activity as well. New shareholdings disclosures should make interesting reading in the next couple of days.
mamcw
17/9/2018
07:16
An upbeat tone to the results. Outlook statement positive, with a please upgrade to analysts revenue expectations and positive EBITDA in H2 "We are excited at the opportunities ahead of the Group as gene editing becomes broadly adopted at industrial scale. We have implemented a new investment strategy, prioritising our identified core growth areas of business, supported by a long-term investment plan that will help drive the scale necessary to meet market demand and fulfil the significant growth potential of the business. We have made a strong start to trading in the second half of the year, including significant new customer relationships in CRISPR screening, continued momentum in our applied products business and a positive trajectory from our research products. We anticipate a second half weighting of revenues in line with previous years, with full year revenues slightly ahead of consensus expectations"
mamcw
14/9/2018
11:09
Shouldn't there be an RNS for this ? Pretty good news.
jurgenklopp
14/9/2018
10:48
14/09/2018 9:27am Business Wire Horizon Discvry (LSE:HZD) Intraday Stock Chart Today : Friday 14 September 2018 Click Here for more Horizon Discvry Charts. AstraZeneca joins Horizon’s Genomics Discovery Initiative CRISPR knockout and activation libraries are a key toolset in early research crRNA libraries are an efficient and convenient platform for gain- and loss-of-function studies Horizon Discovery Group plc (LSE: HZD) (“Horizon̶1; or “the Company”), a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform. AstraZeneca also joins the Genomics Discovery Initiative (GDI), a collaborative functional genomics screening community facilitated by Horizon. AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). The libraries offer a powerful tool for functional genomic screens in drug discovery, providing deeper insight into biological mechanisms for the purpose of understanding disease progression, host-pathogen relationships, drug interactions, and pathway analysis. Horizon’s Edit-R CRISPR-Cas9 synthetic crRNA libraries for both knockout (loss-of-function) and activation (gain-of-function) enable whole genome analysis in an arrayed format, allowing researchers to carry out high-content, multiparametric analyses on a one-well-per-gene basis. The portfolio includes catalog libraries for popular human and mouse gene families, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list. Terry Pizzie, Chief Executive Officer, Horizon Discovery, commented: “Our ongoing relationship with AstraZeneca is providing valuable insights into the scope and capabilities of CRISPR screening, which will be of benefit to the research and discovery community, ultimately bringing drugs to market faster.” Steve Rees, Head of Discovery Biology, IMED Biotech Unit at AstraZeneca, said: “The scientific support and degree of collaboration with the scientists at Horizon has been really impactful in ensuring we are able to harness the full potential of the platform. We have been impressed with the performance of the Edit-R synthetic crRNA, and look forward to feeding our drug discovery pipeline with data generated from the CRISPRa crRNA libraries.”
mamcw
11/9/2018
09:34
a key number to look out for is the revenue forecast for 31/12/18. At the time of the Abcam approach, HZD effectively put out a revenue forecast of £60m for this year, being the consensus of broker forecasts. At the least, this need to be reaffirmed in the outlook statement.
mamcw
10/9/2018
09:15
Results are next Monday - the 17th.
jurgenklopp
06/9/2018
11:47
Yup. Feel that HZD's time has finally come.
mamcw
06/9/2018
08:59
I've taken the view that Woodford, Invesco and ValueAct cannot all of got their due diligence wrong and that HZD is going to deliver. So I've tucked in again at 214p and will sit with this one for the long term.
mamcw
04/9/2018
12:28
Yes, very interesting new holder, and certainly far from passive. The stake has gone into its latest fund, which has a slightly different twist: httPs://www.cnbc.com/2018/01/19/jeff-ubbens-valueact-launching-fund-with-social-goal.html httPs://www.bloomberg.com/news/articles/2018-05-14/valueact-environmental-push-adds-textiles-from-bottles-maker htTps://valueact.com/
rambutan2
04/9/2018
08:24
We should be honoured. ValueAct have taken a 5% stake. These are the guys who spotted the value in the likes of Rolls Royce and have a reputation for shaking up companies and promoting M&A. Effectively, their stake underpins the current price and might yet gets us north of £3. Watch this space.
mamcw
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20181018 11:01:47